SCHEMBL17739571

SCHEMBL17739571

Clc1cc(C2CCOCC2)c2cn[nH]c2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ METAP2 P50579 1/20 0.42
▸ IDO1 P14902 2/20 0.41
▸ TDO2 P48775 1/20 0.41
▸ FAAH O00519 2/20 0.39
▸ ATR Q13535 3/20 0.37
▸ JAK2 O60674 1/20 0.37
▸ JAK1 P23458 1/20 0.37
▸ TYK2 P29597 1/20 0.37
▸ JAK3 P52333 1/20 0.37
▸ ATRIP Q8WXE1 2/20 0.36
▸ NOS1 P29475 1/20 0.36
▸ DYRK1A Q13627 1/20 0.36
▸ PRKAB2 O43741 1/20 0.35
▸ PRKAG1 P54619 1/20 0.35
▸ PRKAA2 P54646 1/20 0.35
▸ PRKAA1 Q13131 1/20 0.35
▸ PRKAG3 Q9UGI9 1/20 0.35
▸ PRKAG2 Q9UGJ0 1/20 0.35
▸ PRKAB1 Q9Y478 1/20 0.35
▸ TRPV1 Q8NER1 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30602751 0.89 METAP2 (0.47) METAP2IDO1TDO2JAK2JAK1
SCHEMBL29092528 0.89 METAP2 (0.47) METAP2IDO1TDO2JAK2JAK1
SCHEMBL17738576 0.85 JAK2 (0.51) METAP2IDO1TDO2JAK2JAK1
SCHEMBL17739276 0.84 METAP2 (0.43) METAP2IDO1TDO2JAK2JAK1
SCHEMBL17731753 0.82 METAP2 (0.42) METAP2IDO1TDO2JAK2JAK1
SCHEMBL21894647 0.82 METAP2 (0.42) METAP2IDO1TDO2ATRJAK2
Hydrochloric Acid SCHEMBL20580499 0.81 METAP2 (0.41) METAP2IDO1TDO2JAK2JAK1
Hydrochloric Acid SCHEMBL30610193 0.81 METAP2 (0.41) METAP2IDO1TDO2JAK2JAK1
SCHEMBL17739257 0.78 CNR1 (0.43) METAP2IDO1TDO2ATRJAK2
SCHEMBL17738596 0.77 RBP4 (0.39) METAP2IDO1TDO2TRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11130738-B2 Pharmaceutical compound IOMET PHARMA LTD. (GB) 2021-09-28 — — US disclosed
US-20200172492-A1 PHARMACEUTICAL COMPOUND IOMET PHARMA LTD. (GB) 2020-06-04 — — US disclosed
US-10590086-B2 Pharmaceutical compound IOMET PHARMA LTD. (GB) 2020-03-17 — — US disclosed
WO-2016071293-A2 PHARMACEUTICAL COMPOUND IOMET PHARMA LTD (GB) 2016-05-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11130738-B2 Pharmaceutical compound IDO1, TDO2, IDO2 METAP2 840/4885IDO1 1/4885TDO2 2/4885
US-20200172492-A1 PHARMACEUTICAL COMPOUND IDO1, TDO2, IDO2 METAP2 840/4885IDO1 1/4885TDO2 2/4885
US-10590086-B2 Pharmaceutical compound IDO1, TDO2, IDO2 METAP2 840/4885IDO1 1/4885TDO2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback